These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7617304)

  • 41. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
    Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
    J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tyrosine-induced release of dopamine is under inhibitory control of presynaptic dopamine D2 and, probably, D3 receptors in the dorsal striatum, but not in the nucleus accumbens.
    Fusa K; Saigusa T; Koshikawa N; Cools AR
    Eur J Pharmacol; 2002 Jul; 448(2-3):143-50. PubMed ID: 12144934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner.
    Liégeois JF; Ichikawa J; Meltzer HY
    Brain Res; 2002 Aug; 947(2):157-65. PubMed ID: 12176156
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study.
    Yan QS; Yan SE
    Eur J Pharmacol; 2001 Apr; 418(1-2):55-64. PubMed ID: 11334865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The dopamine D1 receptor antagonist SCH 23390 can exert D1 agonist-like effects on rat nucleus accumbens neurons.
    Wachtel SR; White FJ
    Neurosci Lett; 1995 Oct; 199(1):13-6. PubMed ID: 8584215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The neuroleptic-like peptide desenkephalin-gamma-endorphin does not antagonize the dopamine receptor agonist-induced inhibition of the release of [3H]dopamine from rat nucleus accumbens slices in vitro.
    Radhakishun FS; Stoof JC; Mulder AH; Versteeg DH; van Ree JM
    Brain Res; 1987 Nov; 426(2):235-42. PubMed ID: 2961411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors.
    Ase AR; Amdiss F; Hébert C; Huang N; van Gelder NM; Reader TA
    J Neural Transm (Vienna); 1999; 106(1):75-105. PubMed ID: 10195336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens.
    Di Matteo V; Di Giovanni G; Di Mascio M; Esposito E
    Neuropharmacology; 1998; 37(2):265-72. PubMed ID: 9680252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
    Hertel P; Nomikos GG; Svensson TH
    Br J Pharmacol; 1997 Dec; 122(8):1639-46. PubMed ID: 9422809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopaminergic modulation of nitric oxide synthase activity in subregions of the rat nucleus accumbens.
    Hoque KE; West AR
    Synapse; 2012 Mar; 66(3):220-31. PubMed ID: 22034069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study).
    Sotnikova TD; Gainetdinov RR; Grekhova TV; Rayevsky KS
    Pharmacol Res; 2001 Mar; 43(3):283-90. PubMed ID: 11401421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine.
    Meltzer HY; Chai BL; Thompson PA; Yamamoto BK
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1452-61. PubMed ID: 8138957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo.
    Ichikawa J; Meltzer HY
    Brain Res; 1992 Mar; 574(1-2):98-104. PubMed ID: 1379112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of clozapine on the efflux of serotonin and dopamine in the rat brain: the role of 5-HT1A receptors.
    Hagino Y; Watanabe M
    Can J Physiol Pharmacol; 2002 Dec; 80(12):1158-66. PubMed ID: 12564641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regionally and functionally distinct serotonin3 receptors control in vivo dopamine outflow in the rat nucleus accumbens.
    De Deurwaerdère P; Moison D; Navailles S; Porras G; Spampinato U
    J Neurochem; 2005 Jul; 94(1):140-9. PubMed ID: 15953357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
    López-Gil X; Artigas F; Adell A
    Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Haloperidol and clozapine: differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatment.
    Hu XT; Wang RY
    Brain Res; 1989 May; 486(2):325-33. PubMed ID: 2786442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of escitalopram and a 5-HT(₁A) receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT(₂C) receptor stimulation; suggestive of antipsychotic potential.
    Hovelsø N; Sager TN; Mørk A
    Pharmacol Biochem Behav; 2011 Jan; 97(3):479-85. PubMed ID: 20937301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.